We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Target for Colon Cancer Treatment

By Biotechdaily staff writers
Posted on 25 Oct 2006
Researchers have discovered a new target for potential uses in future colon cancer treatments--a molecule that is implicated in 85% of colon cancer cases.

The study, performed by researchers from the University of Utah's Huntsman Cancer Institute (Salt Lake City, UT, USA), was published online October 6, 2006, in the Journal of Biological Chemistry. More...
By knocking out (genetically disabling) a molecule called C-terminal binding protein (CTBP), researchers were able to save zebrafish from the effects of a mutation in the adenomatous polyposis coli (APC) gene.

In humans, mutations in this gene have long been known to trigger a series of events that cause colon polyps, which ultimately become cancerous. APC mutations play a role in 85% of colon cancers. The new findings mean CTBP also is involved in that percentage of colon cancers.

In zebrafish, APC mutations keep the intestine from developing correctly. "In essence, knocking out CTPB promotes normal development of the intestine in zebrafish carrying an APC mutation,” stated Dr. David A. Jones, a University of Utah associate professor of oncological sciences and leader of the study.

In normal cells of both humans and zebrafish, the APC gene controls the amount of CTBP present by tagging it for destruction. In tumor cells with mutated APC, CTPB is not destroyed; instead it accumulates in the cell. One function of CTBP is to inactivate the process that converts vitamin A into retinoic acid in the cell. Retinoic acid is essential in cell differentiation--the function that determines what type of cell forms and how long it lives.

This study noted that in both zebrafish and human tissues with APC mutations, there are high CTBP levels and a low capability to produce retinoic acid. In APC-mutated tissues in which CTBP had been knocked out, retinoic acid production was restored. Earlier studies in Dr. Jones' lab demonstrated that the lack of retinoic acid caused zebrafish intestines to form incorrectly, and that adding retinoic acid corrected the problems.

"Knocking out CTBP does exactly the same thing, and the logical conclusion is that it's because CTBP controls retinoic acid production,” remarked Dr. Jones. "Since CTBP is a completely new target, we must now look for potential chemical agents that would work to block its actions. That could take three to five years.”



Related Links:
Huntsman Cancer Institute

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The POC diagnostic test aims to use fingerstick blood, serum, or plasma sample to detect typhoid fever (Photo courtesy of Adobe Stock)

POC Test Uses Fingerstick Blood, Serum, Or Plasma Sample to Detect Typhoid Fever

Typhoid fever is an acute febrile illness caused by Salmonella enterica serovar Typhi (S. Typhi) and affects an estimated 11–21 million people globally each year, resulting in approximately 128,000–161,000... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Industry experts gather at WHX Labs Dubai to discuss how leadership must adapt as AI and automation transform the laboratory (Photo courtesy of Shutterstock)

WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories

WHX Labs in Dubai (formerly Medlab Middle East), held at Dubai World Trade Centre (DWTC) from 10–13 February, brings together international experts to discuss the factors redefining laboratory leadership,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.